CoChat

MASH clinical trials and drugs pipeline: An impending tsunami

Noureddin, Mazen · 2025 · Hepatology
Cited by 48

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Abstract

Metabolic dysfunction–associated steatotic liver disease, formerly known as NAFLD, has ascended to prominence as the predominant chronic liver disease in Western countries and now stands as a leading cause of liver transplantations. In the more advanced stage, metabolic dysfunction–associated steatohepatitis (MASH) may lead to fibrosis, a gateway to cirrhosis, liver cancer, and liver failure. Despite extensive research and exploration of various drug mechanisms, the anticipation for the inaugural approved drug to materialize by 2024 is palpable, marking a significant milestone. Numerous pathways have been investigated for MASH treatment, exploring thyroid hormone receptors, glucagon-like peptides 1, peroxisome proliferator–activated receptors, and agents influencing hepatic steatosis synthesis, inflammatory pathways, genetic components, fibrosis mechanisms, and an array of other avenues. Over time, key regulatory directions have crystallized, now manifesting in 2 primary endpoints under investigation: resolution of steatohepatitis without worsening fibrosis and/or improvement of fibrosis stage without worsening of steatohepatitis, especially used in phase 3 clinical trials, while alternative noninvasive endpoints are explored in phase 2 trials. The prospect of proving efficacy in clinical trials opens doors to combination therapies, evaluating the ideal combination of drugs to yield comprehensive benefits, extending beyond the liver to other organs. Certain combination drug trials are already underway. In this review, we discuss the forefront of MASH drug research as of 2023/2024, illuminating mechanisms, outcomes, and future trajectories. Furthermore, we tackle the challenges confronting MASH trials and propose potential strategies for surmounting them.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/hep.0000000000000860

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 42 references

Research works printed but not linked: 40

  1. Noureddin, 2022, Predicting NAFLD prevalence in the United States using National Health and Nutrition Examination Survey 2017-2018 transient elastography data and application of machine learning, Hepatol Commun, 6, 1537, 10.1002/hep4.1935 · DOI · Paper page
  2. Noureddin, 2018, Pathogenesis of NASH: The impact of multiple pathways, Curr Hepatol Rep, 17, 350, 10.1007/s11901-018-0425-7 · DOI · Paper page
  3. Noureddin, 2020, Drug discovery and treatment paradigms in nonalcoholic steatohepatitis, Endocrinol Diabetes Metab, 3, e00105, 10.1002/edm2.105 · DOI · Paper page
  4. Anania, 2021, Nonalcoholic steatohepatitis: Current thinking from the Division of Hepatology and Nutrition at the Food and Drug Administration, Hepatology, 73, 2023, 10.1002/hep.31687 · DOI · Paper page
  5. Harrison, 2023, Clinical trial landscape in NASH, Clin Gastroenterol Hepatol, 21, 2001, 10.1016/j.cgh.2023.03.041 · DOI · Paper page
  6. Karim, 2023, Resmetirom: An orally administered, smallmolecule, liver-directed, beta-selective THR agonist for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis, touchREV Endocrinol, 19, 60, 10.17925/EE.2023.19.1.60 · DOI · Paper page
  7. Mantovani, 2018, Nonalcoholic fatty liver disease and risk of incident type 2 diabetes: A meta-analysis, Diabetes Care, 41, 372, 10.2337/dc17-1902 · DOI · Paper page
  8. Kleiner, 2005, Design and validation of a histological scoring system for nonalcoholic fatty liver disease, Hepatology, 41, 1313, 10.1002/hep.20701 · DOI · Paper page
  9. Barritt, 2022, Review article: Role of glucagon-like peptide-1 receptor agonists in non-alcoholic steatohepatitis, obesity and diabetes-what hepatologists need to know, Aliment Pharmacol Ther, 55, 944, 10.1111/apt.16794 · DOI
  10. Chin, 2022, The placebo response rate and nocebo events in obesity pharmacological trials. A systematic review and meta-analysis, EClinicalMedicine, 54, 101685, 10.1016/j.eclinm.2022.101685 · DOI
  11. Han, 2019, Rates of and factors associated with placebo response in trials of pharmacotherapies for nonalcoholic steatohepatitis: Systematic review and meta-analysis, Clin Gastroenterol Hepatol, 17, 616, 10.1016/j.cgh.2018.06.011 · DOI · Paper page
  12. Sanyal, 2015, Use of farnesoid X receptor agonists to treat nonalcoholic fatty liver disease, Dig Dis, 33, 426, 10.1159/000371698 · DOI
  13. Younossi, 2022, Obeticholic acid impact on quality of life in patients with nonalcoholic steatohepatitis: REGENERATE 18-month interim analysis, Clin Gastroenterol Hepatol, 20, 2050, 10.1016/j.cgh.2021.07.020 · DOI · Paper page
  14. Ng, 2023, Safety and tolerability of obeticholic acid in chronic liver disease: a pooled analysis of 1878 individuals, Hepatol Commun, 7, e0005, 10.1097/HC9.0000000000000005 · DOI
  15. Basu, 2022, Nonalcoholic fatty liver disease: Review of management for primary care providers, Mayo Clin Proc, 97, 1700, 10.1016/j.mayocp.2022.04.005 · DOI
  16. Chaudhuri, 2023, Efficacy and safety of saroglitazar in real-world patients of non-alcoholic fatty liver disease with or without diabetes including compensated cirrhosis: A tertiary care center experience, JGH Open, 7, 215, 10.1002/jgh3.12878 · DOI
  17. Harrison, 2022, Pemvidutide (ALT-801), a novel GLP-1/glucagon dual receptor agonist, achieves rapid and potent reductions in body weight and liver fat: Results of a placebo-controlled, double-blind, first-in-human (FIH) clinical trial, J Hepatol, 77, S88, 10.1016/S0168-8278(22)00570-0 · DOI
  18. Parker, 2022, Efficacy and safety of cotadutide, a dual glucagon-like peptide-1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney disease, Diabetes Obes Metab, 24, 1360, 10.1111/dom.14712 · DOI · Paper page
  19. Ng, 2022, Meta-analysis: Analysis of mechanistic pathways in the treatment of non-alcoholic steatohepatitis. Evidence from a Bayesian network meta-analysis, Aliment Pharmacol Ther, 55, 1076, 10.1111/apt.16808 · DOI
  20. Sanyal, 2023, Tropifexor for nonalcoholic steatohepatitis: An adaptive, randomized, placebo-controlled phase 2a/b trial, Nat Med, 29, 392, 10.1038/s41591-022-02200-8 · DOI · Paper page
  21. Anstee, 2023, Tropifexor plus cenicriviroc combination versus monotherapy in non-alcoholic steatohepatitis: Results from the phase 2b TANDEM study, Hepatology, 78, 1223, 10.1097/HEP.0000000000000439 · DOI
  22. Harrison, 2022, Aldafermin in patients with non-alcoholic steatohepatitis (ALPINE 2/3): A randomised, double-blind, placebo-controlled, phase 2b trial, Lancet Gastroenterol Hepatol, 7, 603, 10.1016/S2468-1253(22)00017-6 · DOI · Paper page
  23. Loomba, 2024, Pegbelfermin in patients with nonalcoholic steatohepatitis and stage 3 fibrosis (FALCON 1): A randomized phase 2b study, Clin Gastroenterol Hepatol, 22, 102, 10.1016/j.cgh.2023.04.011 · DOI · Paper page
  24. Abdelmalek, 2024, Pegbelfermin in patients with nonalcoholic steatohepatitis and compensated cirrhosis (FALCON 2): A randomized phase 2b study, Clin Gastroenterol Hepatol, 22, 113, 10.1016/j.cgh.2023.04.012 · DOI · Paper page
  25. Loomba, 2023, Twelve-week treatment with BOS-580, a novel, long-acting Fc-FGF-21 fusion protein, leads to a reduction in liver steatosis, liver injury, and fibrosis in patients with phenotypic NASH: A randomized, blinded, placebo-controlled phase 2A trial, J Hepatol, 78, S115, 10.1016/S0168-8278(23)00604-9 · doi:10.1016/s0168-8278(23)00604-9
  26. Amin, 2022, Efficacy and safety of an orally administered DGAT2 inhibitor alone or coadministered with a liver-targeted ACC inhibitor in adults with non-alcoholic steatohepatitis (NASH): Rationale and design of the phase II, dose-ranging, dose-finding, randomised, placebo-controlled MIRNA (Metabolic Interventions to Resolve NASH with fibrosis) study, BMJ Open, 12, e056159, 10.1136/bmjopen-2021-056159 · DOI
  27. O’Farrell, 2023, Multicenter, randomized, double-blind, placebo-controlled trial of Fatty Acid Synthase (FASN) inhibitor, denifanstat, versus placebo in the treatment of biopsy-proven NASH: A 26-week interim analysis of the FASCINATE-2 Phase 2B trial, J Hepatol, 78, S53, 10.1016/S0168-8278(23)00515-9 · DOI
  28. Calle, 2021, ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials, Nat Med, 27, 1836, 10.1038/s41591-021-01489-1 · DOI · Paper page
  29. Noureddin, 2023, Safety and efficacy of once-daily HU6 versus placebo in people with non-alcoholic fatty liver disease and high BMI: A randomised, double-blind, placebo-controlled, phase 2a trial, Lancet Gastroenterol Hepatol, 8, 1094, 10.1016/S2468-1253(23)00198-X · DOI
  30. Rinella, 2020, STELLAR 3 and STELLAR 4: Lessons from the fall of Icarus, J Hepatol, 73, 9, 10.1016/j.jhep.2020.04.034 · DOI
  31. Ratziu, 2020, Cenicriviroc treatment for adults with nonalcoholic steatohepatitis and fibrosis: Final analysis of the phase 2b CENTAUR study, Hepatology, 72, 892, 10.1002/hep.31108 · DOI · Paper page
  32. Ichikawa, 2007, Role of growth hormone, insulin-like growth factor 1 and insulin-like growth factor-binding protein 3 in development of non-alcoholic fatty liver disease, Hepatol Int, 1, 287, 10.1007/s12072-007-9007-4 · DOI
  33. Hua, 2014, Low serum sex hormone-binding globulin is associated with nonalcoholic fatty liver disease in type 2 diabetic patients, Clin Endocrinol (Oxf), 80, 877, 10.1111/cen.12360 · DOI · Paper page
  34. Kim, 2012, A low level of serum total testosterone is independently associated with nonalcoholic fatty liver disease, BMC Gastroenterol, 12, 69, 10.1186/1471-230X-12-69 · DOI · Paper page
  35. Harrison, 2022, Rencofilstat, a cyclophilin inhibitor: A phase 2a, multicenter, single-blind, placebo-controlled study in F2/F3 NASH, Hepatol Commun, 6, 3379, 10.1002/hep4.2100 · DOI
  36. Harrison, 2021, A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes, Nat Commun, 12, 5503, 10.1038/s41467-021-25701-5 · DOI
  37. Sanyal, 2010, Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis, N Engl J Med, 362, 1675, 10.1056/NEJMoa0907929 · DOI · Paper page
  38. Davison, 2020, Suboptimal reliability of liver biopsy evaluation has implications for randomized clinical trials, J Hepatol, 73, 1322, 10.1016/j.jhep.2020.06.025 · DOI · Paper page
  39. Brunt, 2022, Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD, J Hepatol, 76, 1030, 10.1016/j.jhep.2022.01.011 · DOI · Paper page
  40. Rich, 2021, Racial and ethnic disparities in non-alcoholic fatty liver disease in the USA, Lancet Gastroenterol Hepatol, 6, 422, 10.1016/S2468-1253(21)00100-X · DOI

Cited by

See all 48

Metadata

Authors
Noureddin, M.
Venue
Hepatology
Published
2024-03-19
Volume
82
Issue
5
Pages
1325-1340
ISSN
  • 0270-9139 (ISSN-L)
  • 1527-3350
OpenAlex
W4392939270
Cited by
48
References
42
FWCI
12.55
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: MASH clinical trials and drugs pipeline: An impending tsunami. https://app.cochat.ai/papers/10.1097/hep.0000000000000860
The paper
Noureddin, M. (2025). MASH clinical trials and drugs pipeline: An impending tsunami. Hepatology. https://doi.org/10.1097/hep.0000000000000860

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.